SCHEMBL29759454

SCHEMBL29759454

Cc1ccc(C(NC(=O)CC[C@H](NC(=O)OCC2c3ccccc3-c3ccccc32)C(=O)O)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 6/20 0.54
TLR2 O60603 2/20 0.53
MDM4 O15151 2/20 0.50
TP53 P04637 2/20 0.50
CASP3 P42574 1/20 0.44
SLC17A5 Q9NRA2 1/20 0.42
TNF P01375 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20592527 1.00 MDM2 (0.54) MDM2TLR2MDM4TP53CASP3
SCHEMBL20592524 1.00 MDM2 (0.54) MDM2TLR2MDM4TP53CASP3
SCHEMBL29750297 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL1755686 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL29401774 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL29651368 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL31217659 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL13227676 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL29350848 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3
SCHEMBL120503 0.94 TLR2 (0.55) MDM2TLR2MDM4TP53CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577274-B2 Manufacture of glucagon peptides BACHEM HOLDING AG (CH) 2026-03-17 US disclosed
EP-4058184-B1 APPARATUS AND METHOD FOR ITERATIVE POLYMER SYNTHESIS BACHEM AG (CH) 2025-06-04 EP disclosed
EP-4532531-A1 PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 ScinoPharm Taiwan, Ltd. (TW) 2025-04-09 EP disclosed
EP-3728304-B1 SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES BACHEM HOLDING AG (CH) 2025-02-12 EP disclosed
CN-114929376-B Apparatus and method for iterative polymer synthesis 巴克姆股份公司 2024-10-01 CN disclosed
CN-111670194-B Preparation of glucagon peptides 巴赫姆控股股份公司 2024-01-26 CN disclosed
US-20230406900-A1 PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 SCINOPHARM TAIWAN, LTD. (TW) 2023-12-21 US disclosed
WO-2023234860-A1 PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 SCINOPHARM TAIWAN LTD. (TW) 2023-12-07 WO disclosed
US-20220387958-A1 APPARATUS AND METHOD FOR ITERATIVE POLYMER SYNTHESIS BACHEM AG (CH) 2022-12-08 US disclosed
EP-3746466-B1 MANUFACTURE OF GLUCAGON PEPTIDES BACHEM AG (CH) 2022-11-23 EP disclosed
CN-115181157-A Method for preparing disulfide bond-containing polypeptide by solid-liquid phase combination 湖北健翔生物制药有限公司 2022-10-14 CN disclosed
EP-4058184-A1 APPARATUS AND METHOD FOR ITERATIVE POLYMER SYNTHESIS Bachem AG (CH) 2022-09-21 EP disclosed
EP-3433267-B1 METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES BACHEM HOLDING AG (CH) 2022-08-24 EP disclosed
CN-114929376-A Apparatus and method for iterative polymer synthesis 巴克姆股份公司 2022-08-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387958-A1 APPARATUS AND METHOD FOR ITERATIVE POLYMER SYNTHESIS POLI, PUF60, PCNA MDM2 3240/4885TLR2 2674/4885MDM4 1958/4885
US-20230406900-A1 PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 GLP1R, IAPP, GCG MDM2 2682/4885TLR2 4630/4885MDM4 3675/4885
US-12577274-B2 Manufacture of glucagon peptides IAPP, GLP1R, GCG MDM2 4043/4885TLR2 3591/4885MDM4 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.